The development of targeted gene delivery systems has become a pivotal focus in lung cancer research, aiming to improve the specificity and efficiency of therapeutic nucleic acid delivery while minimizing off-target effects and toxicity. Lung cancer presents unique challenges for gene delivery due to the complex architecture of lung tissue, the presence of mucus barriers,…
Patient-derived xenograft (PDX) models have become an invaluable tool in lung cancer research, providing a more clinically relevant platform for studying tumor biology and therapeutic responses. Unlike traditional cell line xenografts, PDX models involve implanting fresh tumor tissues directly obtained from lung cancer patients into immunodeficient mice. This approach preserves the histological architecture, genetic heterogeneity,…
In lung cancer research, selecting an appropriate transfection method is crucial for efficient genetic manipulation, which underpins studies on gene function, drug resistance, and therapeutic development. The two broad categories of transfection techniques—chemical and physical—each present distinct advantages and limitations when applied to lung cancer cell lines, influencing experimental outcomes and reproducibility. Chemical transfection methods…
Gene silencing through small interfering RNA (siRNA) transfection has become an indispensable tool in lung squamous cell carcinoma (SCC) research. By specifically targeting and degrading messenger RNA (mRNA) transcripts, siRNA enables researchers to transiently knock down gene expression, facilitating the study of gene function, signaling pathways, and the identification of therapeutic targets in lung SCC…
Transfection efficiency—the proportion of cells successfully taking up and expressing foreign genetic material—is a critical parameter in lung cancer functional genomics studies. High transfection efficiency ensures that a sufficient number of cells express the gene of interest or silenced target, enabling reliable downstream analysis such as gene function, signaling pathways, and drug response mechanisms. Lung…
Lipid nanoparticles (LNPs) have emerged as a transformative platform for delivering RNA molecules, such as mRNA and siRNA, into lung tumor cells. These nanoscale carriers protect RNA from enzymatic degradation, facilitate cellular uptake, and enable efficient release of their cargo into the cytoplasm, overcoming major barriers in gene therapy and molecular research. The unique physiological…
Transfecting non-adherent lung cancer cells presents unique technical challenges due to their growth characteristics and membrane properties. Unlike adherent cells that grow attached to surfaces, many lung cancer cell lines—especially those derived from small cell lung carcinoma or circulating tumor cells—grow in suspension, making traditional transfection methods less effective. Non-adherent cells often exhibit reduced uptake…
CRISPR/Cas9 genome editing technology has revolutionized functional genomics and therapeutic development by enabling precise, efficient, and versatile modification of DNA sequences. In lung adenocarcinoma research, CRISPR/Cas9 facilitates the study of gene function, identification of cancer drivers, and development of targeted therapies. However, delivering CRISPR components effectively into lung adenocarcinoma cell lines such as A549, HCC827,…
Electroporation remains one of the most effective physical methods for introducing nucleic acids such as DNA, RNA, and CRISPR components into lung cancer cells, especially those that are difficult to transfect using chemical reagents. This technique uses short, high-voltage electrical pulses to transiently permeabilize the cell membrane, allowing charged molecules to enter the cytoplasm. Over…
The process of gene expression following RNA transfection typically involves several key steps. Here’s an overview of how this process works, focusing on mRNA transfection as an example: 1. Transfection The first step is the actual process of transfection, where the RNA molecules are introduced into the cells. This can be done using a variety…
